Malignant Media InfarctionONSITENCT06939114
Optic Nerve Sonography to Monitor Intracranial Pressure After Ischemic sTrokE - The ONSITE Study
An observational study of Malignant Media Infarction and Stroke, run by University of Zurich at 1 site in Switzerland.
Trial summary
The goal of the ONSITE study is to investigate whether an increase Optic nerve sheath diameter (ONSD) may help to predict intracranial hypertension (IH) after stroke. IH is a life-threatening complicaitons of malignant middle cerebral artery (MCA) infarction due to space-occupying brain edema. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Malignant Media Infarction, Stroke, Intracranial Hypertension
- How many people
- 107 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2019to 31 Mar 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: For non-stroke, non-IH patients we will recruit patients hospitalized at the Department of Neurology, University Hospital of Zurich. Patients within the clinic are screened for inclusion / exclusion criteria. If a patient is considered eligible for the study, he or she will be contacted by a member of the study team. For stroke patients acute stroke patients admitted to the Department of Neurology, University Hospital of Zurich will be screened for study eligibility. If a patient is considered eligible for the study, he or she will be contacted by a member of the study team after initial emergency care is completed.
Who may be able to join
- ≥ 18 years of age
- Consent according to the regulations of research in an emergency situation
- For non-Control patients: Acute ischemic stroke within 24 hours of recruitment
Who cannot join
- Known intracranial space-occupying lesion
- Known history of intracranial hypertension
- Contra-indications on ethical grounds
- Expected or known non-compliance to participate in the observational study, severe drug- or/and alcohol abuse
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Zurich
Zurich, Canton of Zurich, 8091
About this study
The goal of the ONSITE study is to investigate whether an increase Optic nerve sheath diameter (ONSD) may help to predict intracranial hypertension (IH) after stroke. IH is a life-threatening complicaitons of malignant middle cerebral artery (MCA) infarction due to space-occupying brain edema. Patients at risk are monitored based on clinical symptoms, which can be difficult due to comorbidities such as delirium or systemic infections, which can hempen clinical judgement. Readily available, non-invasive methods to monitor ICP in stroke patients could help to earlier diagnose rising ICP and facilitate treatment decisions such as hemicraniectomy. This study investigates whether ONSD with optic nerve sonography (ONS) can detect brain edema after stroke.
Read the detailed description
Intracranial Hypertension (IH) is a life-threatening complication after ischemic and hemorrhagic stroke. IH develops in ischemic stroke due to brain edema, which may occur in large-vessel occlusion, most common in large middle cerebral artery (MCA) infarcts due to occlusion of the internal carotid artery (ICA) or occlusion of the proximal segment (M1) of the middle cerebral artery. Up to 30% of patients with occlusion of these vessels develop large space-occupying brain edema leading to a serious condition termed "malignant media infarction" leading to rapid neurological deterioration and reduced consciousness. IH usually develops within the first 24-96 hours after stroke; however, the exact time course is not predictable.
IH is a life-threatening emergency that demands immediate medical or surgical action. As it is not possible to predict the course of intracerebral pressure increase in patients at risk, it is necessary to monitor these patients closely. However, clinical observation of neurological symptoms may be hampered, as stroke patients often require pain or anxiolytic medications or suffer from typical comorbidities of stroke, such as infection, cardiac diseases, or delirium, which limit judgment of neurological symptoms. Despite the limitations of clinical symptom prediction for IH, ICP is not routinely monitored in stroke patients as invasive intracranial devices, the current gold standard for ICP monitoring have several drawbacks that limit their routine application. Intracranial ICP monitors require a neurosurgical intervention, which may not always be feasible or contraindicated in several conditions such as coagulopathy and thrombocytopenia. Furthermore, ICP monitors are associated with complications such as hemorrhages (1.1-5.8% of cases), infection (0-15% of cases) or monitor malfunction (6.3-40% of cases).
Because of these limitations, noninvasive methods to measure ICP have been eagerly sought. Se-rial computer tomography (CT) or Magnetic Resonance Imaging (MRI) are applied to detect in-creased ICP in patients at risk. However, imaging is expensive, potential harmful to patients due to radiation or necessity to lie supine and still for a prolonged period and have limited availability. As such, their use is restricted as well. Furthermore there are studies suggesting that CT scans might have a poor sensitivity for detection of IH.
Ultrasonography is an alternative tool to measure ICP non-invasively. Ultrasonography is a low cost, simple bedside tool, widely available in emergency rooms as well as on stroke units. Optic nerve sonography (ONS) to measure the optic nerve sheath diameter (ONSD) has been developed and suggested as an alternative sonographic method to detect IH. ONS utilizes the fact that the optic nerve sheath, which is readily visualized by transorbital ultrasound, is filled with spinal fluid and grows in diameter according to ICP. To perform ONS, the patient is placed in a position 20̊ supine to horizontal. The probe is then placed on the temporal side of the closed eyelid without pressure to avoid any damage to the eye. The position of the probe is then adjusted until the entry of the optic nerve into the globe of the eye is visible. ONSD is measured 3 mm behind the globe, as this position shows the greatest distension of the optic sheath in IH patients and thus has become the standard measurement point.
The method is quickly learned and a trained operator can perform measurement of ONSD in both eyes in less than 4 minutes. In current clinical practice, ONS has been used in intensive care setting to monitor ICP and diagnose brain death in brain trauma patients. ONS is also used in other neurological diseases, such as idiopathic intracranial hypertension. It was shown in several studies, as well as meta-analyses that ONS derived measurements of intracranial hypertension can be performed with good intra- and interobserver reliability. In a meta-analysis, in which ONDS was compared to invasive ICP measurements, ONSD showed good test accuracy with a pooled sensitivity of 90% and pooled specificity of 85%. When compared to CT scan, ONSD showed good accuracy for IH as well, with a sensitivity of 95.6% and specificity of 92.3%. ONSD can also be used to rapidly assess the success of therapeutic interventions. For example, patients with idiopathic intracranial hypertension showed a significantly reduced ONSD directly af-ter lumbar puncture with therapeutic removal of 30-50 ml of cerebrospinal fluid (CSF).
Several studies raised the question of which cut-off value should be used for the ONSD in healthy individuals. Earlier studies that compared ONSD to CT results suggested a upper normal value of 4.5 mm for individuals aged ≤1 year and 5.0 mm for those aged >1 year. More recent studies, however, comparing ONSD to invasive ICP measurements, suggested that a cut-off value of 5.7-6.0mm provided the best accuracy and that values above that cut off should alert the clinician of IH.
Preliminary data from routine evaluation of ONSD in patients with stroke and ICH showed significantly increased ONSD on the side of stroke compared to the contralateral side. The investigators also tested for the feasibility of the method in patients with diagnosed idiopathic intracranial hyper-tension, which were found to have larger ONSD than healthy individuals on both sides. In each patient, 3 individual measurements per eye were averaged.
The goal of this study is to improve stroke patient care by helping to investigate whether ONS is a feasible tool to diagnose IH after stroke, as IH is one of the most troublesome and life-threatening complications of large-vessel ischemic stroke. It is critical that the clinician does not miss rising ICP so that life-saving treatment is not delayed. ONS measurement of ICP is an accurate, widely avail-able and easy to learn method to detect IH and has been successfully used in clinical practice in several fields of neurology. Its value in acute stroke care, however, remains uncertain. The investigators have tested ONS derived ONSD measurements and have confirmed the feasibility to use this parameter. If ONSD thresholds can be established to detect IH early after stroke, it could be further tested in a clinical trial to aid in decision making for hemicraniectomy in stroke patients.
This study aims to investigate the hypothesis that ONS is a feasible method to detect IH in stroke patients. To this end, the primary objective is to observe the changes in ONSD after large-vessel ischemic stroke and in the presence of IH.
The second objective is to derive a cut-off value for ONSD that best predicts the presence of IH in stroke patients and to assess whether this cut-off value would be able to detect IH before clinical changes occur (assessed by the Glasgow Coma Scale (GCS) and/or National Institutes of Health Stroke Scale (NIHSS) in patients at risk). This cut-off value could be the base for a future clinical trial to evaluate the diagnostic performance of this method in stroke patients. In addition, the investigators aim to investigate the predictive value of the ONSD in the clinical outcome after stroke (as derived from the modified Rankin Scale (mRS) and NIHSS after 3 month).
- Keywords
- Stroke, Ischemic Stroke, Ultrasound, Optic nerve sheath, Optic nerve sheath diameter, Malignant media infarction, Intracranial pressure, Intracranial hypertension, Large vessel occlusion stroke
- Medical subject headings
- Stroke, Intracranial Hypertension, Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Stroke | Patient with acute ischemic stroke | |
| Non-Stroke, non-IH controls | Patient without acute stroke or history of intracranial hypertension |
What is being measured
The primary outcome is the main question the study is designed to answer.
Presence of intracranial hypertension
Intracranial hypertension is defined in our study as midline shift ≥ 3mm or a decrease in GCS without any other cause based on clinical judgement or patient requiring hemicraniectomy.
Measured: Assessed at Baseline, at 12 hours after stroke, at 24 hours after stroke, at 36 hours after stroke, at 48 hours after stroke, at 72 hours after stroke, at 120 hours after stroke.
Secondary outcomes (3)
National Institutes of Health Stroke Scale (NIHSS)
The National Institutes of Health Stroke Scale (NIHSS) is a 11-point neurological exam used to quantify the severity of an acute stroke. The NIHSS assesses level of consciousness, eye move-ments, visual fields, facial muscle function, extremity strength, sensory function, coordination, language, speech, and neglect. It is a commonly used tool in clinical routine, as well as in stroke re-search.
Measured: Obtained at Baseline, at 12 hours after stroke, at 24 hours after stroke, at 36 hours after stroke, at 48 hours after stroke, at 72 hours after stroke, at 120 hours after stroke, at 3 months after stroke
Glasgow Coma Scale (GCS)
The Glasgow Coma Scale (GCS) is a 3-point neurological exam used to assess the level of con-sciousness of a patient. The GCS consists of an assessment of eye response, verbal response and motor response.
Measured: Obtained at Baseline, at 12 hours after stroke, at 24 hours after stroke, at 36 hours after stroke, at 48 hours after stroke, at 72 hours after stroke, at 120 hours after stroke, at 3 months after stroke
modified Rankin Scale (mRS)
The modified Rankin Scale (mRS) is a widely used scale of measuring the degree of disability of people who have suffered a stroke. The mRS is used in clinical practice, as well as in stroke studies to describe the clinical outcome after stroke. The mRS runs from 0 to 6, with 0 being a patient with-out any disability and 6 indicating for death of the patient.
Measured: mRS is measured 3 months after stroke
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2025
- Study start1 Jan 2019
- Primary completion31 Mar 2024
- Study completion31 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Malignant Media InfarctionStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 107 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Susanne Wegener, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06939114
- Sponsor's protocol ID
- 2018-01946
- Other IDs
- 2018
- Acronym
- ONSITE
- Status last verified
- Apr 2025
- First submitted
- 4 Apr 2025
- Last updated
- 22 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Will be decided upon reasonable request
Publications
Bauerle J, Nedelmann M. Sonographic assessment of the optic nerve sheath in idiopathic intracranial hypertension. J Neurol. 2011 Nov;258(11):2014-9. doi: 10.1007/s00415-011-6059-0. Epub 2011 Apr 28.
PubMed 21523461Bauerle J, Lochner P, Kaps M, Nedelmann M. Intra- and interobsever reliability of sonographic assessment of the optic nerve sheath diameter in healthy adults. J Neuroimaging. 2012 Jan;22(1):42-5. doi: 10.1111/j.1552-6569.2010.00546.x. Epub 2010 Dec 1.
PubMed 21121998Toscano M, Spadetta G, Pulitano P, Rocco M, Di Piero V, Mecarelli O, Vicenzini E. Optic Nerve Sheath Diameter Ultrasound Evaluation in Intensive Care Unit: Possible Role and Clinical Aspects in Neurological Critical Patients' Daily Monitoring. Biomed Res Int. 2017;2017:1621428. doi: 10.1155/2017/1621428. Epub 2017 Mar 21.
PubMed 28421189Tayal VS, Neulander M, Norton HJ, Foster T, Saunders T, Blaivas M. Emergency department sonographic measurement of optic nerve sheath diameter to detect findings of increased intracranial pressure in adult head injury patients. Ann Emerg Med. 2007 Apr;49(4):508-14. doi: 10.1016/j.annemergmed.2006.06.040. Epub 2006 Sep 25.
PubMed 16997419Ohle R, McIsaac SM, Woo MY, Perry JJ. Sonography of the Optic Nerve Sheath Diameter for Detection of Raised Intracranial Pressure Compared to Computed Tomography: A Systematic Review and Meta-analysis. J Ultrasound Med. 2015 Jul;34(7):1285-94. doi: 10.7863/ultra.34.7.1285.
PubMed 26112632Hansen HC, Helmke K. The subarachnoid space surrounding the optic nerves. An ultrasound study of the optic nerve sheath. Surg Radiol Anat. 1996;18(4):323-8. doi: 10.1007/BF01627611.
PubMed 8983112Hansen HC, Helmke K. Validation of the optic nerve sheath response to changing cerebrospinal fluid pressure: ultrasound findings during intrathecal infusion tests. J Neurosurg. 1997 Jul;87(1):34-40. doi: 10.3171/jns.1997.87.1.0034.
PubMed 9202262Galetta S, Byrne SF, Smith JL. Echographic correlation of optic nerve sheath size and cerebrospinal fluid pressure. J Clin Neuroophthalmol. 1989 Jun;9(2):79-82.
PubMed 2526162Dubourg J, Javouhey E, Geeraerts T, Messerer M, Kassai B. Ultrasonography of optic nerve sheath diameter for detection of raised intracranial pressure: a systematic review and meta-analysis. Intensive Care Med. 2011 Jul;37(7):1059-68. doi: 10.1007/s00134-011-2224-2. Epub 2011 Apr 20.
PubMed 21505900Ropper AH, Shafran B. Brain edema after stroke. Clinical syndrome and intracranial pressure. Arch Neurol. 1984 Jan;41(1):26-9. doi: 10.1001/archneur.1984.04050130032017.
PubMed 6606414Schwab S, Aschoff A, Spranger M, Albert F, Hacke W. The value of intracranial pressure monitoring in acute hemispheric stroke. Neurology. 1996 Aug;47(2):393-8. doi: 10.1212/wnl.47.2.393.
PubMed 8757010Wijdicks EF, Sheth KN, Carter BS, Greer DM, Kasner SE, Kimberly WT, Schwab S, Smith EE, Tamargo RJ, Wintermark M; American Heart Association Stroke Council. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Apr;45(4):1222-38. doi: 10.1161/01.str.0000441965.15164.d6. Epub 2014 Jan 30.
PubMed 24481970Heiss WD. Malignant MCA Infarction: Pathophysiology and Imaging for Early Diagnosis and Management Decisions. Cerebrovasc Dis. 2016;41(1-2):1-7. doi: 10.1159/000441627. Epub 2015 Nov 19.
PubMed 26581023Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996 Apr;53(4):309-15. doi: 10.1001/archneur.1996.00550040037012.
PubMed 8929152Hofmeijer J, Algra A, Kappelle LJ, van der Worp HB. Predictors of life-threatening brain edema in middle cerebral artery infarction. Cerebrovasc Dis. 2008;25(1-2):176-84. doi: 10.1159/000113736. Epub 2008 Jan 23.
PubMed 18212524
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optic Nerve Sonography to Monitor Intracranial Pressure After Ischemic sTrokE - The ONSITE Study
- ClinicalTrials.gov ID
- NCT06939114
- Acronym / sponsor ID
- ONSITE / 2018-01946
- Keywords
- Stroke, Ischemic Stroke, Ultrasound, Optic nerve sheath, Optic nerve sheath diameter, Malignant media infarction, Intracranial pressure, Intracranial hypertension
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 107 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- 1 Jan 2019 (actual)
- Primary completion
- 31 Mar 2024 (actual)
- Study completion
- 31 Mar 2024 (actual)
- First posted
- 22 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of the ONSITE study is to investigate whether an increase Optic nerve sheath diameter (ONSD) may help to predict intracranial hypertension (IH) after stroke. IH is a life-threatening complicaitons of malignant middle cerebral artery (MCA) infarction due to space-occupying brain edema. Patients at risk are monitored based on clinical symptoms, which can be difficult due to comorbidities such as delirium or systemic infections, which can hempen clinical judgement. Readily available, non-invasive methods to monitor ICP in stroke patients could help to earlier diagnose rising ICP and facilitate treatment decisions such as hemicraniectomy. This study investigates whether ONSD with optic nerve sonography (ONS) can detect brain edema after stroke.
Detailed description
Intracranial Hypertension (IH) is a life-threatening complication after ischemic and hemorrhagic stroke. IH develops in ischemic stroke due to brain edema, which may occur in large-vessel occlusion, most common in large middle cerebral artery (MCA) infarcts due to occlusion of the internal carotid artery (ICA) or occlusion of the proximal segment (M1) of the middle cerebral artery. Up to 30% of patients with occlusion of these vessels develop large space-occupying brain edema leading to a serious condition termed "malignant media infarction" leading to rapid neurological deterioration and reduced consciousness. IH usually develops within the first 24-96 hours after stroke; however, the exact time course is not predictable.
IH is a life-threatening emergency that demands immediate medical or surgical action. As it is not possible to predict the course of intracerebral pressure increase in patients at risk, it is necessary to monitor these patients closely. However, clinical observation of neurological symptoms may be hampered, as stroke patients often require pain or anxiolytic medications or suffer from typical comorbidities of stroke, such as infection, cardiac diseases, or delirium, which limit judgment of neurological symptoms. Despite the limitations of clinical symptom prediction for IH, ICP is not routinely monitored in stroke patients as invasive intracranial devices, the current gold standard for ICP monitoring have several drawbacks that limit their routine application. Intracranial ICP monitors require a neurosurgical intervention, which may not always be feasible or contraindicated in several conditions such as coagulopathy and thrombocytopenia. Furthermore, ICP monitors are associated with complications such as hemorrhages (1.1-5.8% of cases), infection (0-15% of cases) or monitor malfunction (6.3-40% of cases).
Because of these limitations, noninvasive methods to measure ICP have been eagerly sought. Se-rial computer tomography (CT) or Magnetic Resonance Imaging (MRI) are applied to detect in-creased ICP in patients at risk. However, imaging is expensive, potential harmful to patients due to radiation or necessity to lie supine and still for a prolonged period and have limited availability. As such, their use is restricted as well. Furthermore there are studies suggesting that CT scans might have a poor sensitivity for detection of IH.
Ultrasonography is an alternative tool to measure ICP non-invasively. Ultrasonography is a low cost, simple bedside tool, widely available in emergency rooms as well as on stroke units. Optic nerve sonography (ONS) to measure the optic nerve sheath diameter (ONSD) has been developed and suggested as an alternative sonographic method to detect IH. ONS utilizes the fact that the optic nerve sheath, which is readily visualized by transorbital ultrasound, is filled with spinal fluid and grows in diameter according to ICP. To perform ONS, the patient is placed in a position 20̊ supine to horizontal. The probe is then placed on the temporal side of the closed eyelid without pressure to avoid any damage to the eye. The position of the probe is then adjusted until the entry of the optic nerve into the globe of the eye is visible. ONSD is measured 3 mm behind the globe, as this position shows the greatest distension of the optic sheath in IH patients and thus has become the standard measurement point.
The method is quickly learned and a trained operator can perform measurement of ONSD in both eyes in less than 4 minutes. In current clinical practice, ONS has been used in intensive care setting to monitor ICP and diagnose brain death in brain trauma patients. ONS is also used in other neurological diseases, such as idiopathic intracranial hypertension. It was shown in several studies, as well as meta-analyses that ONS derived measurements of intracranial hypertension can be performed with good intra- and interobserver reliability. In a meta-analysis, in which ONDS was compared to invasive ICP measurements, ONSD showed good test accuracy with a pooled sensitivity of 90% and pooled specificity of 85%. When compared to CT scan, ONSD showed good accuracy for IH as well, with a sensitivity of 95.6% and specificity of 92.3%. ONSD can also be used to rapidly assess the success of therapeutic interventions. For example, patients with idiopathic intracranial hypertension showed a significantly reduced ONSD directly af-ter lumbar puncture with therapeutic removal of 30-50 ml of cerebrospinal fluid (CSF).
Several studies raised the question of which cut-off value should be used for the ONSD in healthy individuals. Earlier studies that compared ONSD to CT results suggested a upper normal value of 4.5 mm for individuals aged ≤1 year and 5.0 mm for those aged >1 year. More recent studies, however, comparing ONSD to invasive ICP measurements, suggested that a cut-off value of 5.7-6.0mm provided the best accuracy and that values above that cut off should alert the clinician of IH.
Preliminary data from routine evaluation of ONSD in patients with stroke and ICH showed significantly increased ONSD on the side of stroke compared to the contralateral side. The investigators also tested for the feasibility of the method in patients with diagnosed idiopathic intracranial hyper-tension, which were found to have larger ONSD than healthy individuals on both sides. In each patient, 3 individual measurements per eye were averaged.
The goal of this study is to improve stroke patient care by helping to investigate whether ONS is a feasible tool to diagnose IH after stroke, as IH is one of the most troublesome and life-threatening complications of large-vessel ischemic stroke. It is critical that the clinician does not miss rising ICP so that life-saving treatment is not delayed. ONS measurement of ICP is an accurate, widely avail-able and easy to learn method to detect IH and has been successfully used in clinical practice in several fields of neurology. Its value in acute stroke care, however, remains uncertain. The investigators have tested ONS derived ONSD measurements and have confirmed the feasibility to use this parameter. If ONSD thresholds can be established to detect IH early after stroke, it could be further tested in a clinical trial to aid in decision making for hemicraniectomy in stroke patients.
This study aims to investigate the hypothesis that ONS is a feasible method to detect IH in stroke patients. To this end, the primary objective is to observe the changes in ONSD after large-vessel ischemic stroke and in the presence of IH.
The second objective is to derive a cut-off value for ONSD that best predicts the presence of IH in stroke patients and to assess whether this cut-off value would be able to detect IH before clinical changes occur (assessed by the Glasgow Coma Scale (GCS) and/or National Institutes of Health Stroke Scale (NIHSS) in patients at risk). This cut-off value could be the base for a future clinical trial to evaluate the diagnostic performance of this method in stroke patients. In addition, the investigators aim to investigate the predictive value of the ONSD in the clinical outcome after stroke (as derived from the modified Rankin Scale (mRS) and NIHSS after 3 month).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Stroke | – | –Patient with acute ischemic stroke |
| Non-Stroke, non-IH controls | – | –Patient without acute stroke or history of intracranial hypertension |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- For non-stroke, non-IH patients we will recruit patients hospitalized at the Department of Neurology, University Hospital of Zurich. Patients within the clinic are screened for inclusion / exclusion criteria. If a patient is considered eligible for the study, he or she will be contacted by a member of the study team. For stroke patients acute stroke patients admitted to the Department of Neurology, University Hospital of Zurich will be screened for study eligibility. If a patient is considered eligible for the study, he or she will be contacted by a member of the study team after initial emergency care is completed.
Key inclusion criteria (3 listed)
- ≥ 18 years of age
- Consent according to the regulations of research in an emergency situation
- For non-Control patients: Acute ischemic stroke within 24 hours of recruitment
Key exclusion criteria (4 listed)
- Known intracranial space-occupying lesion
- Known history of intracranial hypertension
- Contra-indications on ethical grounds
- Expected or known non-compliance to participate in the observational study, severe drug- or/and alcohol abuse
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Presence of intracranial hypertension
Time frame: Assessed at Baseline, at 12 hours after stroke, at 24 hours after stroke, at 36 hours after stroke, at 48 hours after stroke, at 72 hours after stroke, at 120 hours after stroke.
Intracranial hypertension is defined in our study as midline shift ≥ 3mm or a decrease in GCS without any other cause based on clinical judgement or patient requiring hemicraniectomy.
3 secondary outcomes
National Institutes of Health Stroke Scale (NIHSS)
Time frame: Obtained at Baseline, at 12 hours after stroke, at 24 hours after stroke, at 36 hours after stroke, at 48 hours after stroke, at 72 hours after stroke, at 120 hours after stroke, at 3 months after stroke
Glasgow Coma Scale (GCS)
Time frame: Obtained at Baseline, at 12 hours after stroke, at 24 hours after stroke, at 36 hours after stroke, at 48 hours after stroke, at 72 hours after stroke, at 120 hours after stroke, at 3 months after stroke
modified Rankin Scale (mRS)
Time frame: mRS is measured 3 months after stroke
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2025.
- Background: PubMed 21523461Bauerle J, Nedelmann M. Sonographic assessment of the optic nerve sheath in idiopathic intracranial hypertension. J Neurol. 2011 Nov;258(11):2014-9. doi: 10.1007/s00415-011-6059-0. Epub 2011 Apr 28.
- Background: PubMed 21121998Bauerle J, Lochner P, Kaps M, Nedelmann M. Intra- and interobsever reliability of sonographic assessment of the optic nerve sheath diameter in healthy adults. J Neuroimaging. 2012 Jan;22(1):42-5. doi: 10.1111/j.1552-6569.2010.00546.x. Epub 2010 Dec 1.
- Background: PubMed 28421189Toscano M, Spadetta G, Pulitano P, Rocco M, Di Piero V, Mecarelli O, Vicenzini E. Optic Nerve Sheath Diameter Ultrasound Evaluation in Intensive Care Unit: Possible Role and Clinical Aspects in Neurological Critical Patients' Daily Monitoring. Biomed Res Int. 2017;2017:1621428. doi: 10.1155/2017/1621428. Epub 2017 Mar 21.
- Background: PubMed 16997419Tayal VS, Neulander M, Norton HJ, Foster T, Saunders T, Blaivas M. Emergency department sonographic measurement of optic nerve sheath diameter to detect findings of increased intracranial pressure in adult head injury patients. Ann Emerg Med. 2007 Apr;49(4):508-14. doi: 10.1016/j.annemergmed.2006.06.040. Epub 2006 Sep 25.
- Background: PubMed 26112632Ohle R, McIsaac SM, Woo MY, Perry JJ. Sonography of the Optic Nerve Sheath Diameter for Detection of Raised Intracranial Pressure Compared to Computed Tomography: A Systematic Review and Meta-analysis. J Ultrasound Med. 2015 Jul;34(7):1285-94. doi: 10.7863/ultra.34.7.1285.
- Background: PubMed 8983112Hansen HC, Helmke K. The subarachnoid space surrounding the optic nerves. An ultrasound study of the optic nerve sheath. Surg Radiol Anat. 1996;18(4):323-8. doi: 10.1007/BF01627611.
- Background: PubMed 9202262Hansen HC, Helmke K. Validation of the optic nerve sheath response to changing cerebrospinal fluid pressure: ultrasound findings during intrathecal infusion tests. J Neurosurg. 1997 Jul;87(1):34-40. doi: 10.3171/jns.1997.87.1.0034.
- Background: PubMed 2526162Galetta S, Byrne SF, Smith JL. Echographic correlation of optic nerve sheath size and cerebrospinal fluid pressure. J Clin Neuroophthalmol. 1989 Jun;9(2):79-82.
- Background: PubMed 21505900Dubourg J, Javouhey E, Geeraerts T, Messerer M, Kassai B. Ultrasonography of optic nerve sheath diameter for detection of raised intracranial pressure: a systematic review and meta-analysis. Intensive Care Med. 2011 Jul;37(7):1059-68. doi: 10.1007/s00134-011-2224-2. Epub 2011 Apr 20.
- Background: PubMed 6606414Ropper AH, Shafran B. Brain edema after stroke. Clinical syndrome and intracranial pressure. Arch Neurol. 1984 Jan;41(1):26-9. doi: 10.1001/archneur.1984.04050130032017.
- Background: PubMed 8757010Schwab S, Aschoff A, Spranger M, Albert F, Hacke W. The value of intracranial pressure monitoring in acute hemispheric stroke. Neurology. 1996 Aug;47(2):393-8. doi: 10.1212/wnl.47.2.393.
- Background: PubMed 24481970Wijdicks EF, Sheth KN, Carter BS, Greer DM, Kasner SE, Kimberly WT, Schwab S, Smith EE, Tamargo RJ, Wintermark M; American Heart Association Stroke Council. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Apr;45(4):1222-38. doi: 10.1161/01.str.0000441965.15164.d6. Epub 2014 Jan 30.
- Individual participant dataSharing planned: Undecided. Will be decided upon reasonable request
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Malignant Media Infarction and Stroke, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Presence of intracranial hypertension (time frame: Assessed at Baseline, at 12 hours after stroke, at 24 hours after stroke, at 36 hours after stroke, at 48 hours after stroke, at 72 hours after stroke, at 120 hours after stroke.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06939114, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2025.